Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells.
Hasegawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Yoshida T, Sakai T, Koyano T, Kam TS, Murata K, Sugahara K, Tsuruda K, Akamatsu N, Tsukasaki K, Masuda M, Takasu N, Kamihira S. Hasegawa H, et al. Among authors: masuda m. Blood. 2006 Jan 15;107(2):679-88. doi: 10.1182/blood-2005-05-1982. Epub 2005 Sep 29. Blood. 2006. PMID: 16195335 Free article.
A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production.
Hasegawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Sunazuka T, Izuhara T, Sugahara K, Tsuruda K, Masuda M, Takasu N, Tsukasaki K, Tomonaga M, Kamihira S. Hasegawa H, et al. Among authors: masuda m. Blood. 2007 Sep 1;110(5):1664-74. doi: 10.1182/blood-2007-01-068981. Epub 2007 Jun 5. Blood. 2007. PMID: 17551094 Free article. Clinical Trial.
Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines.
Matsuda T, Almasan A, Tomita M, Uchihara JN, Masuda M, Ohshiro K, Takasu N, Yagita H, Ohta T, Mori N. Matsuda T, et al. Among authors: masuda m. J Virol. 2005 Feb;79(3):1367-78. doi: 10.1128/JVI.79.3.1367-1378.2005. J Virol. 2005. PMID: 15650163 Free PMC article. Retracted.
Transactivation of CCL20 gene by Epstein-Barr virus latent membrane protein 1.
Okudaira T, Yamamoto K, Kawakami H, Uchihara JN, Tomita M, Masuda M, Matsuda T, Sairenji T, Iha H, Jeang KT, Matsuyama T, Takasu N, Mori N. Okudaira T, et al. Among authors: masuda m. Br J Haematol. 2006 Feb;132(3):293-302. doi: 10.1111/j.1365-2141.2005.05877.x. Br J Haematol. 2006. PMID: 16409294 Free article. Retracted.
Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells.
Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Takasu N, Matsuda T, Ohta T, Tanaka Y, Ohshiro K, Mori N. Tomita M, et al. Among authors: masuda m. Int J Cancer. 2006 Feb 1;118(3):765-72. doi: 10.1002/ijc.21389. Int J Cancer. 2006. PMID: 16106398 Free article. Retracted.
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; Japan Clinical Oncology Group Study JCOG9801. Tsukasaki K, et al. Among authors: masuda m. J Clin Oncol. 2007 Dec 1;25(34):5458-64. doi: 10.1200/JCO.2007.11.9958. Epub 2007 Oct 29. J Clin Oncol. 2007. PMID: 17968021 Clinical Trial.
2,640 results